BMD Loss Slowed With Delayed Antiretroviral Therapy in HIV
Researchers examined the benefits and risks associated with delaying ART initiation to slow bone mineral density loss.
Researchers examined the benefits and risks associated with delaying ART initiation to slow bone mineral density loss.
After parathyroidectomy, morbidity and mortality rates were considerably higher in patients with secondary and tertiary vs primary hyperparathyroidism.
Healthy middle-age patients who took colecalciferol did not have a reduced risk for fall or fracture.
Although metformin did not improve glycemic control in patients with type 1 diabetes, the treatment did improve cardiovascular disease risk management.
Gonadotropin-releasing hormone antagonist elagolix demonstrated clinical improvement for women with endometriosis-related pain.
Liraglutide does not increase the risk for acute pancreatitis in patients with type 2 diabetes who are also at high risk for cardiovascular events.
Long-term denosumab increased bone mineral density in postmenopausal women.
No between-group differences for factors such as glycemic control, endogenous glucose production, and insulin sensitivity were found.
Both mealtime and postmeal faster insulin aspart are noninferior to mealtime conventional insulin aspart, regarding HbA1c change from baseline.
After 1 year of therapy, men who underwent testosterone therapy experienced improvement in bone mineral density and mood.